{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:20:16Z","timestamp":1782836416419,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research Foundation of Jiangsu provincial commission of health and family planning","award":["M2021016"],"award-info":[{"award-number":["M2021016"]}]},{"name":"Research Foundation of Jiangsu provincial commission of health and family planning","award":["ZD2022067"],"award-info":[{"award-number":["ZD2022067"]}]},{"name":"Special project for academic improvement of department heads of Jiangsu Province Hospital of CM","award":["Y2021ZR24"],"award-info":[{"award-number":["Y2021ZR24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03599-x","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T01:01:44Z","timestamp":1721782904000},"page":"660-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Somatic and germline aberrations in homologous recombination repair genes among Chinese high-risk breast cancer patients by multi-gene next-generation sequencing"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1938-8425","authenticated-orcid":false,"given":"Ling","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanYing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeLe","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiFen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"3","key":"3599_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3599_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","volume":"41","author":"S Lei","year":"2021","unstructured":"Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021;41(11):1183\u201394.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"3599_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110\u201320.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3599_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100049","volume":"36","author":"KD Doig","year":"2023","unstructured":"Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol. 2023;36(3): 100049.","journal-title":"Mod Pathol"},{"key":"3599_CR5","unstructured":"Chinese Expert Consensus on Clinical Diagnosis and Treatment of Familial Hereditary Tumors (2021 Edition)-Familial Hereditary Breast Cancer Family Genetic Oncology Professional Committee of China Anti-Cancer Association. Chin J Clin Oncol. 2021;48(23):1189\u20131194"},{"key":"3599_CR6","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"3599_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255\u201382.","journal-title":"Target Oncol"},{"key":"3599_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2022.10.021","volume":"179","author":"TJ Herzog","year":"2023","unstructured":"Herzog TJ, Vergote I, Gomella LG, et al. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective. Eur J Cancer. 2023;179:136\u201346.","journal-title":"Eur J Cancer"},{"issue":"5","key":"3599_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"9","key":"3599_CR10","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.gim.2022.07.001","volume":"24","author":"P Horak","year":"2022","unstructured":"Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24(9):1991.","journal-title":"Genet Med"},{"issue":"7418","key":"3599_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"1","key":"3599_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","volume":"9","author":"C Chen","year":"2023","unstructured":"Chen C, Lin CJ, Pei YC, et al. Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell Discov. 2023;9(1):125.","journal-title":"Cell Discov"},{"issue":"269","key":"3599_CR13","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal."},{"key":"3599_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102650","volume":"121","author":"L Incorvaia","year":"2023","unstructured":"Incorvaia L, Perez A, Marchetti C, et al. Theragnostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window? Cancer Treat Rev. 2023;121: 102650.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3599_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR. Pharmacokinetics and Pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022;61(12):1649\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"3599_CR16","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23(20):6113\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3599_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/jamaoncol.2019.0620","volume":"5","author":"YS Yap","year":"2019","unstructured":"Yap YS, Lu YS, Tamura K, et al. Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 2019;5(10):1489\u201396.","journal-title":"JAMA Oncol"},{"issue":"38","key":"3599_CR18","doi-asserted-by":"publisher","first-page":"25025","DOI":"10.18632\/oncotarget.24382","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Shin VY, Chai X, et al. Breast and ovarian cancer penetrance of BRCA1\/2 mutations among Hong Kong women. Oncotarget. 2018;9(38):25025\u201333.","journal-title":"Oncotarget"},{"issue":"3","key":"3599_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/humu.23965","volume":"41","author":"X Gao","year":"2020","unstructured":"Gao X, Nan X, Liu Y, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Hum Mutat. 2020;41(3):696\u2013708.","journal-title":"Hum Mutat"},{"issue":"10","key":"3599_CR20","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00432-017-2465-8","volume":"143","author":"G Li","year":"2017","unstructured":"Li G, Guo X, Tang L, et al. Analysis of BRCA1\/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. J Cancer Res Clin Oncol. 2017;143(10):2011\u201324.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3599_CR21","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/ijc.32877","volume":"146","author":"H Meng","year":"2020","unstructured":"Meng H, Yao L, Yuan H, et al. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients. Int J Cancer. 2020;146(11):3044\u201352.","journal-title":"Int J Cancer"},{"issue":"2","key":"3599_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-023-01488-0","volume":"26","author":"GR Daly","year":"2024","unstructured":"Daly GR, AlRawashdeh MM, McGrath J, et al. PARP inhibitors in breast cancer: a short communication. Curr Oncol Rep. 2024;26(2):103\u2013113.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"3599_CR23","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"10","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;10(7):11479.","journal-title":"Nat Commun"},{"key":"3599_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsx038","volume":"4","author":"L Hoffman-Andrews","year":"2018","unstructured":"Hoffman-Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. J Law Biosci. 2018;4:648\u201357.","journal-title":"J Law Biosci"},{"issue":"7","key":"3599_CR25","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1093\/oncolo\/oyae021","volume":"29","author":"J Chen","year":"2024","unstructured":"Chen J, Zhu Y, Wei Wu, et al. Association between homologous recombin- ation repair defect status and long-term prognosis of early HER2-low breast cancer: a retrospective cohort study. Oncologist. 2024;29(7):e864\u2013e876.","journal-title":"Oncologist"},{"key":"3599_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s13353-024-00848-1","author":"YS Li","year":"2024","unstructured":"Li YS, Jiang HC. Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer. J Appl Genet. 2024 https:\/\/doi.org\/10.1007\/s13353-024-00848-1.","journal-title":"J Appl Genet"},{"key":"3599_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12282-021-01283-4","volume":"29","author":"SJ Koh","year":"2022","unstructured":"Koh SJ, Ohsumi S, Takahashi M, et al. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer. 2022;29:92\u2013102.","journal-title":"Breast Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03599-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:22:15Z","timestamp":1738254135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03599-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"12 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}